Q1 2022

Filed May 13, 2022 · 10-Q · 43 days after period end · 0001493152-22-013243

Q1 2022 · 10-Q

Revenue—

Net Income

-$678.05K

N/M vs Q1 2021

EPS, diluted—

Operating Income-$609,236N/M

Operating Cash Flow-$459,571N/M

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	—	—	$756.00	$41.55K
Net Income	-$678.05K	-$461.68K	-$153.21K	$53.96K
EPS Diluted	—	-$0.01	-$0.50	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR